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Abstract
Casitas B-lineage lymphoma-b (Cbl-b) is a ubiquitin ligase (E3) that modulates signaling by tagging molecules for
degradation. It is a complex protein with multiple domains and binding partners that are not involved in ubiquitinating
substrates. Herein, we demonstrate that Cbl-b, but not c-Cbl, is recruited to the clustered B cell antigen receptor (BCR) and
that Cbl-b is required for entry of endocytosed BCRs into late endosomes. The E3 activity of Cbl-b is not necessary for BCR
endocytic trafficking. Rather, the ubiquitin associated (UBA) domain is required. Furthermore, the Cbl-b UBA domain is
sufficient to confer the receptor trafficking functions of Cbl-b on c-Cbl. Cbl-b is also required for entry of the Toll-like
receptor 9 (TLR9) into late endosomes and for the in vitro activation of TLR9 by BCR-captured ligands. These data indicate
that Cbl-b acts as a scaffolding molecule to coordinate the delivery of the BCR and TLR9 into subcellular compartments
required for productively delivering BCR-captured ligands to TLR9.
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Introduction
Antigen presentation by B lymphocytes is required to mount
high affinity humoral immune responses, for coordinating antigen
specific cytotoxicity, and for propagating some T cell responses
[1]. B lymphocytes differ from other antigen presenting cells in
several fundamental ways. The most important difference is that B
cells are clonotypic, and they usually only efficiently capture and
process antigens recognized by the B cell antigen receptor (BCR)
[2]. The primacy of the BCR as the portal for entry of antigen
ensures coordination of B and T cell responses.
In B cells, most antigens are processed in specialized MHC class
II containing late endosomes (MIIC) [3] which are Lamp-1+,
acidic and contain cathepsins, thiol reductases, and other
molecules required for efficient antigen processing [4]. MIIC
vesicles consist of a limiting membrane studded with Lamp-1 and
a lumen containing multivesicular bodies [5]. These intraluminal
vesicles are derived from BCR-laden transport vesicles that have
gained access to the MIIC compartment [6].
BCR trafficking to late endosomes is also required for coupling
antigen recognition to the activation of the toll-like receptors
(TLRs) 7 and 9 [7,8]. This is because these receptors only
productively bind ligands in late endosomes. The mechanisms
underlying this requirement have been best defined for TLR9. In
resting B cells, TLR9 resides outside the MIIC. Upon BCR
ligation, TLR9 rapidly transits into the MIIC [9,10] where the
receptor can bind DNA containing complexes captured by the
endocytosed BCR [11–13]. Analysis of BCR and TLR9 endocytic
trafficking in anergic B cells, in which the trafficking of both
receptors is aberrant, indicates that entry of the BCR and TLR9
into late endosomes is coordinated and that both receptors enter
on common transport vesicles [10]. Presumably, this facilitates the
transfer of BCR captured ligands to the TLRs.
Work from several laboratories has provided a general model
for how endocytosed receptor complexes are sorted through early
endosomes and delivered into late endosomal multivesicular
bodies [14]. Central to this model is the monoubiquitination of
receptors and the recognition of these ubiquitins by a protein
complex containing Hrs, Eps15 and STAM (the endosomal
complex required for transport, ESCRT-0). ESCRT-0 engaged
receptors are retained within the endosomal pathway while
unbound receptors recycle to the cell surface. Successive
recruitment of the multimeric complexes ESCRT-I, ESCRT-II,
and ESCRT-III target receptors to late endosomes. These
receptors are then sorted into intraluminal multivesicular bodies
where they are degraded. While the ESCRT complexes constitute
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e89792
the core machinery for the delivery of receptors to late endosomes,
several other molecular complexes are involved in facilitating and
regulating ESCRT-mediated endocytic transit [15].
Previously, we have demonstrated that the BCR subunit Igb is
ubiquitinated and that this is required for sorting to late
endosomes [16]. Normal receptor ubiquitination required Itch, a
member of the Nedd4 family of E3s. This is in apparent contrast
to the T cell receptor (TCR) [17], and other receptors [15], where
recruitment of the Casitas B-lineage Lymphoma (Cbl) E3s to the
tyrosine phosphorylated receptor induce ubiquitination. We now
report that Cbl-b is also required for BCR endocytic trafficking,
and that it contributes to receptor ubiquitination following
receptor stimulation. However, Cbl-b ligase activity is dispensible
for BCR endocytic trafficking. Rather, Cbl-b provides a necessary
scaffolding function that is dependent upon the carboxyterminal
tail. Surprisingly, transit of TLR9 into late endosomes was also
dependent upon Cbl-b. These and other findings demonstrate a
unique, unexpected, and functionally important role for Cbl-b in
directing the delivery of both the BCR and TLR9 to late
endosomes.
Materials and Methods
Mice
Wild-type, Cblb2/2 (Balb/c), and CblbC373A (C57BL/6J) [18]
mice were housed in the animal facilities of the University of
Chicago. Mice were used at 8 to 12 weeks of age, and experiments
were in accordance with the guidelines of the Institutional Animal
Care and Use Committee of the University of Chicago (Protocol
Number: 71577, approval date 4/6/13). All animal studies were
carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. All mice were sacrificed by CO2 inhalation
followed by cervical dislocation.
Cells and culture conditions
Splenic B cells were isolated by negative selection using
biotinylated anti-CD11b (M1/70), anti-CD11c (HL3), anti-
NK1.1 (PK136), anti-Ter-119, anti-CD3e1452C11, anti-CD4
(RM4-5), anti-CD8a (53-6.7), anti-Ly-6G, and Ly-6C (RB6-8C5,
all BD Bioscience) followed by streptavidin magnetic beads
(MACS; Miltenyi Biotec) [16]. Cells were cultured for 20 hours
in complete DMEM supplemented with 10% FCS, 50 ng/ml rIL-
4 (R & D Systems), and 7.5 mg/ml anti-CD-40 (BD Biosciences).
Receptor internalization and ubiquitination assays
BCR internalization assays on wild-type and Cblb2/2 splenic B
cells were performed as previously described [19]. Receptor
ubiquitination assays were performed as described [16].
Retroviral gene transduction
The cDNA encoding human Cbl-b and truncation mutants as
well as human c-Cbl [20] were subcloned into the plasmid
MIGR1. Calcium Phosphate transfection of PlatE cells with
MIGR1 was carried out as previously described [21,22]. Aliquots
of cell lysates were immunoblotted to confirm the size of the
expressed proteins. Cbl-b (H-454 and H-121) and c-Cbl (C-15)
antibodies were from Santa Cruz Biotechnology. Wt and Cblb2/2
B cells were transduced by resuspending in viral supernatant with
8 mg/ml polybrene in the presence of rIL-4 (50 ng/ml) and anti-
CD40 (7.5 mg/ml) and centrifuging at 10006g for 1.5 hr at room
temperature. The cells were then washed and placed into fresh
culture medium and allowed to grow for 48 hrs.
Confocal microscopy
Confocal Microscopy was performed as previously described
[10]. Images were collected by using a Leica TCS SP2 AOBS
confocal microscope. Antibodies used for visualization were
Lamp-1 (1D4B) (BD Biosciences), TLR9 (26C593.2) (Imgenex),
Cathepsin L (CPLH-3G10) and Cbl-b (H-121 and H-454) (Santa
Cruz Biotechnology). All secondary antibodies were Alexa Fluor
conjugated IgG (H & L) from Invitrogen. To quantitate the extent
of colocalization between 2, 3 or 4 fluorescent markers in
individual cells, we used the JACoP plug-in of ImageJ. The
specific algorithm used was based on the Mander’s coefficient with
a threshold of 40 [23]. Cells that had a Mander’s coefficient of
0.25 or higher were scored as positive for co-localization. For each
experiment, at least 30 randomly selected cells were scored.
T-bet assay and quantitative real-time PCR
Biotinylated ODN 1826 and biotinylated control ODN were
from Invivogen. Purified splenic B cells from WT and Cblb2/2
mice were incubated with 10 mg/ml of streptavidin-conjugated
F(ab)2 Ig (H & L) followed by either the biotinylated ODN 1826 or
control ODN (Invivogen). Cells were then incubated for 6 hrs at
37uC. RNA was isolated and quantitative PCR performed as
previously described [10].
Western blotting and immunoprecipitations
Splenic B cells were purified by negative selection as described
above. Cells were stimulated with 20 mg/ml F(ab)2 goat anti–
mouse Ig (H+L) (Jackson ImmunoResearch Laboratories) at 37uC
for indicated times. Cell aliquots were lysed in 1% NP40 buffer
(150 mM NaCl, 10 mM Tris HCl pH 7.7, 5 mM EDTA, 0.4 mM
sodium orthovanadate, and 10 mM sodium pyrophosphate)
containing mini EDTA-free protease inhibitor cocktail tablets
(Roche), phenylmethylsulfonyl fluoride (PMSF)(Sigma-Aldrich),
20 mM N-Ethylmaleimide (NEM) (Sigma-Aldrich), 10 mM 1,10-
phenatholine monohydrate (OPD) (Sigma-Aldrich), and 50 mM
PR-619 (LifeSensors). Lysates were clarified by centrifugation at
4uC. Lysates were precleared with protein A–Sepharose (Pierce),
incubated with primary antibodies specific for Igb (Hm79b, BD
Biosciences) and captured with protein G–Sepharose (Pierce).
Lysates or immunoprecipitates were resolved on a 4–15% Mini-
Protean TGX gel (Bio-Rad) and transferred onto Immun-Blot
PVDF membrane (Bio-Rad). Membranes were probed with
antibodies specific for ubiquitin (P4D1, Santa Cruz), Igb [24] or
Cbl-b.
Statistical Analyses
Statistical comparisons were made using the Student’s t-test.
Results
Cbl-b is required for BCR endocytic trafficking to late
endosomes
To explore if Cbl-b played a role in BCR endocytic trafficking,
splenic B lymphocytes [10] from wild type (WT) or Cblb2/2 Balb/
c mice were isolated and then stimulated in vitro through the BCR
with FITC-conjugated anti-Ig F(ab)2 antibodies for 30 minutes at
37uC. Aliquots were then fixed, stained with anti-Lamp-1
antibodies (Alexa Fluor 647, Invitrogen), and visualized by
confocal microscopy [10]. Representative images are provided in
Figure 1A, and a quantitative analysis of the fraction of cells
demonstrating significant overlap (.25%) between the BCR and
Lamp-1 is provided in Figure 1B [10]. In WT cells, the BCR
rapidly targeted Lamp-1+ late endosomes with almost all cells
Cbl-b Is Required for BCR Endocytic Trafficking
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demonstrating strong co-localization between the BCR and Lamp-
1. In contrast, in Cblb2/2 cells there was little co-localization
between the BCR and Lamp-1. Rather, the endocytosed BCR was
in close proximity with Lamp-1+ late endosomes. Similar results
were obtained if cells were stimulated for 60 minutes (data not
shown).
We hypothesized that in the absence of Cbl-b, endocytosed
BCRs might target terminal lysosomes which in B lymphocytes, do
not contain Lamp-1 [25]. As demonstrated in Figures 1A and
1B, the Lamp-12 subcellular compartment targeted by the BCR
in Cblb2/2 splenocytes contained cathespin L. Interestingly,
Cathepsin L was much more apparent in the Lamp-1+ compart-
ments of WT than Cblb2/2 splenocytes. This latter observation
suggests that Cbl-b lies in the signaling pathway necessary for
BCR-mediated MIIC maturation [10,26,27].
To determine if Cbl-b contributed to BCR endocytic trafficking
by ubiquitinylating Igb, splenic B lymphocytes from WT or
Cblb2/2 mice were stimulated with anti-Ig F(ab)2 antibodies for
Figure 1. Cbl-b is required for normal trafficking to late endosomes. (A–B) Trafficking to Lamp-1+ and Cathepsin L+ endocytic compartments
by the ligated BCR in WT and Cblb2/2 splenic B cells. (A) Representative confocal images of BCR stimulated cells (30 min) and (B) quantitative analysis
of three independent experiments (30 cells/exp) (*p = 0.0003 and **p= 0.0004). Average Mander’s coefficient of BCR vs Lamp-1 for WT cells was
0.55660.12 vs 0.14660.07 for Cblb2/2 cells (p,0.0001). Average Mander’s coefficient of Cathepsin-L vs Lamp-1 for WT cells was 0.41560.05 vs
0.17960.03 for Cbl-b2/2 cells (p,0.002). (C) Ubiquitination of Igb in Cblb2/2 and WT splenocytes. Unstimulated or BCR stimulated splenocytes were
lysed, immunoprecipitated with anti-Igb antibodies, and then sequentially immunoblotted with anti-Ub (upper panel) or anti-Igb (lower panel)
antibodies. Results are representative of three experiments. (D) Cells were stimulated as in ‘‘A’’ for two minutes, fixed, and visualized by confocal
microscopy. Shown are the percentages of each cell population that formed a receptor cap on the cell surface containing more than 50% of
visualized BCRs (n = 3 experiments, p = 0.005). (E) Internalization of BCR in Cblb2/2 (blue, diamonds) and WT (purple, squares) splenocytes in response
to anti-IgM F(ab)2 antibodies. Results are representative of three experiments.
doi:10.1371/journal.pone.0089792.g001
Cbl-b Is Required for BCR Endocytic Trafficking
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15 minutes at 37uC. Aliquots were then lysed in a buffer
containing 1% NP40, and lysates were precipitated with anti-
Igbantibodies. Precipitations were resolved by SDS-PAGE,
transferred to PVDF membranes, and probed with anti-ubiquitin
(Ub) antibodies. As can be seen in Figure 1C, there was
approximately a three-fold decrease in the amount of ubiquiti-
nated Igb immunoprecipitated from Cblb2/2 B cells following
BCR stimulation. These results indicate that Cbl-b, along with the
E3 ligase Itch [16], contributes to inductive Igb ubiquitination.
Recently, in chicken B cell lines, Cbl has been demonstrated to
be required for ligand-induced BCR clustering on the cell surface
[28]. Therefore, cells were stimulated as above for two minutes
and then visualized by confocal microscopy. As demonstrated in
Figure 1D, while more than 80% of WT B cells formed a cap
following BCR stimulation, only approximately 35% of Cbl-b2/2
B cells formed caps (p = 0.005). These data indicate that Cbl-b is
required for BCR clustering in primary murine splenocytes.
Despite the difference in capping, subsequent internalization of
the ligated BCR on both WT and Cblb2/2 splenic B cells were
similar (Figure 1E). Furthermore, transit of the ligated BCR to
EEA1+ early endosomes was similar in WT and Cblb2/2 splenic B
cells (Figure S1) [10]. However, Cblb2/2 BCRs left this
compartment much more rapidly that WT BCRs. These data
indicate that Cbl-b is specifically required for two discrete
processes, BCR clustering and trafficking between early and late
endosomes.
Rapid recruitment of Cbl-b following BCR stimulation
To examine if Cbl-b directly participated in BCR endocytic
trafficking, we first determined if Cbl-b was recruited to the BCR
following receptor engagement. Splenic WT Balb/c B lympho-
cytes were stimulated as above with Texas Red-conjugated anti-Ig
F(ab)2 antibodies for various times up to 60 minutes. Cells were
then fixed, stained with anti-Lamp-1 (Alexa Fluor 647) and anti-
Cbl-b antibodies (Alexa Fluor 488, Invitrogen), and visualized by
confocal microscopy. Representative images are provided in
Figure 2A with the corresponding quantitations from three
independent experiments provided in Figure 2B. As can be seen,
Cbl-b was rapidly and almost completely recruited to the BCR
within two minutes of ligation. The BCR and Cbl-b remained co-
localized as the receptor was internalized and targeted to late
endosomes. However, the association between the BCR and Cbl-b
diminished as the BCR started to enter Lamp-1+ late endosomes.
These data indicate that Cbl-b is rapidly and robustly recruited to
the BCR and then traffics with the receptor through the endocytic
pathway. However, the majority of Cbl-b does not enter Lamp-1+
late endosomes with the BCR.
The Cbl-b UBA domain, but not the RING finger domain,
are required for BCR endocytic trafficking
We next examined which functional domains of Cbl-b were
required for BCR endocytic trafficking. For these experiments,
cDNAs encoding WT Cbl-b and a series of Cbl-b mutants
(Figure 3A) [20,29] were cloned into the retroviral vector
MIGR1. These vectors were then packaged in PlatE cells [21].
Aliquots of cell lysates from packaging cells were immunoblotted
to confirm expression of Cbl-b proteins of the expected relative
molecular weights (Figure 3B). Splenic B cells were harvested
from Cblb2/2 mice and cultured for 24 hours in IL-4 (50 ng/ml)
and anti-CD40 antibodies (7.5 mg/ml). Aliquots of proliferating
Cblb2/2 splenic B cells were then infected with viruses encoding
the indicated Cbl-b molecules. After an additional 48 hours, cells
were stimulated with Texas Red conjugated anti-BCR F(ab2)
antibody fragments for 30 minutes, then fixed and stained with
anti-Lamp-1 and anti-Cbl-b antibodies. Finally, cells expressing
each construct (typically 30–40% of cells) were visualized by
confocal microscopy (Figure 3C). A quantitative assessment of
the degree of colocalization between the BCR and Lamp-1 in
MIGR1 infected Cblb2/2 cells is provided in Figure 3D (n = 3
experiments). As can be seen, retroviral mediated expression of
WT Cbl-b reconstituted BCR trafficking to late endosomes, while
there was no reconstitution mediated by vector alone. Examina-
tion of the various mutants indicated that the C-terminal domain,
which lacks the tyrosine kinase-binding (TKB) domain, could
reconstitute BCR trafficking as could a Cbl-b molecule lacking E3
activity (Cbl-bC373A). In contrast, a mutant lacking the C-terminal
UBA domain could not. Interestingly, expression of Cbl-bGYDAQ,
in which the Ub binding motif within the UBA domain [20,29]
was mutated, reconstituted BCR trafficking. These data indicate
that the Cbl-b UBA domain, but not the ability of the UBA
domain to bind ubiquitin, is necessary for BCR endocytic
trafficking.
To confirm that the E3 activity of Cbl-b was dispensable for
BCR endocytic trafficking, we obtained mice in which gene
targeting had been used to derive mice expressing Cbl-b bearing
the C373A mutation [18]. Spleens from these mice or WT
controls were harvested and splenic B cells isolated and stimulated
as described above. Aliquots were then fixed, stained, and
visualized by confocal microscopy. Representative images are
provided in Figure 4A, and quantitative assessments from three
independent experiments are depicted in Figure 4B. These data
indicate that BCR endocytic trafficking was similar in WT and
CblbC373A B splenocytes. These results indicate that, although Cbl-
b contributes to the ubiquitination of Igb, this function is
dispensible or redundant for BCR endocytic trafficking.
Our data indicated that the carboxyterminal domain of Cbl-b,
which contains the UBA domain, was required for BCR endocytic
trafficking. This finding was potentially revealing as the amino
acid sequences of c-Cbl and Cbl-b are divergent in the UBA
domain. Therefore, we next examined if ectopic expression of c-
Cbl in Cblb2/2 splenocytes could restore BCR endocytic
trafficking.
A cDNA encoding WT c-Cbl (Figure 5A) was cloned into
MIGRI and packaged in PlatE cells (anti-c-Cbl immunoblots
provided in Figure 5B). Packaged virus was used to infect
Cblb2/2 splenocytes which were assayed by confocal microscopy
(Figure 5C) and scored for reconstitution of BCR endocytic
trafficking (Figure 5D) as described above. As can be seen,
ectopic expression of c-Cbl did not reconstitute BCR endocytic
trafficking in Cblb2/2 B splenocytes. In keeping with these results,
confocal microscopic analysis of WT splenocytes revealed that, in
contrast to Cbl-b, c-Cbl was not recruited to the ligated BCR
complex (Figure S2).
We next examined if the UBA domain of Cbl-b, in the context
of c-Cbl, was sufficient to reconstitute BCR endocytic trafficking.
To this end, we constructed a cDNA encoding a chimeric c-Cbl
molecule in which the UBA domain of c-Cbl was replaced with
that of Cbl-b (c-CblDUBA-Cbl-b)(Figure 5A–D). This chimeric
molecule was then expressed in Cblb2/2 splenocytes and cells were
analyzed by confocal microscopy. Expression of c-CblDUBA-Cbl-b
restored normal BCR endocytic trafficking. These observations
indicate that the unique ability of Cbl-b to mediate endocytic
trafficking is fully encoded within the carboxyterminal region
containing the UBA domain.
Cbl-b Is Required for BCR Endocytic Trafficking
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Cbl-b is required for TLR9 endocytic trafficking and for
TLR9-dependent B cell responses in vivo
In addition to inducing rapid endocytic transit of the BCR,
receptor stimulation induces the translocation of TLR9 into late
endosomes [9,10]. Therefore, we next examined if Cbl-b was
required for BCR ligation-induced TLR9 transit. B splenocytes
from WT, Cblb2/2, and CblbC373A mice were stimulated as in
Figure 1 for 30 minutes and then analyzed by confocal microscopy
for the co-localization of the BCR, Lamp-1 and TLR9. As can be
seen in Figures 6A–6C, in Cblb2/2 mice, stimulation of the BCR
induced the co-localization of the endocytosed BCR with TLR9.
However, both receptors were excluded from Lamp-1+ late
endosomes. As expected, this compartment was Cathepsin L+
consistent with terminal lysosomes (Figure S3). In contrast, both
the BCR and TLR9 entered late endosomes in B splenocytes from
CblbC373A mice. No staining of TLR9 was observed in splenic B
cells from TLR92/2 mice [10]. These data indicate that TLR9 has
similar Cbl-b requirements as the BCR for entry into late
endosomes.
As in Cblb2/2 splenocytes TLR9 was sequestered within
terminal lysosomes, we examined if these cells were unresponsive
to TLR9 ligands delivered through the BCR. A unique
downstream target of TLR9 is the transcription factor T-box
expressed in T cells (T-bet), which can be directly activated by
CpG via TLR9 in B cells through an IFNcR/STAT1-independent
pathway [30]. Therefore, WT and Cblb2/2 splenic B cells were
incubated with streptavidin-conjugated F(ab)2 anti-IgG antibodies
followed by biotinylated ODN 1826 or control ODN (Invivogen).
After six hours, RNA was isolated from stimulated B cells, and T-
bet mRNA expression was assayed by quantitative PCR. IFNc
stimulated cells were used as a positive control [30]. As can be seen
in Figure 6D, BCR targeted ODN 1826 stimulated T-bet
expression in WT cells. The control ODN did not induce T-bet
expression. However, in Cblb2/2 splenocytes ODN 1826 failed to
induce T-bet. These data reveal a defect in T-bet responses to
TLR9 ligands in Cblb2/2 splenocytes. T-bet induction was also
defective through IFNcsuggesting the presence of more global
activation defects.
Discussion
Herein, we demonstrate that recruitment of Cbl-b to the BCR is
necessary for both clustering the BCR on the cell surface and for
guiding internalized BCRs into late endosomes. This activity of
Cbl-b was unique and could not be supplanted by c-Cbl.
Furthermore, Cbl-b was required for TLR9 entry into late
endosomes and for activation of TLR9 by BCR captured ligands.
In the absence of Cbl-b, the BCR and TLR9 became sequestered
together within terminal lysosomes. These data indicate that Cbl-b
plays an important role in coupling adaptive and innate immune
signaling responses in B lymphocytes.
Our findings both confirm and extend recent observations in
chicken cell lines on the importance of Cbl in determining BCR
endocytic fate. As observed in chicken cell lines [28], Cbl-b was
required for ligand-induced clustering on the cell surface. In these
cell line studies, Cbl played a role in coupling the BCR to the
motor protein dynein. Dynein has also been implicated in
endocytic trafficking [31] indicating that the observed defects in
clustering and endocytic trafficking could reflect a common
underlying mechanism.
The unique ability of Cbl-b to facilitate receptor endocytic
trafficking mapped to the Cbl-b carboxyl-terminal tail that
contains the UBA domain. One well-described difference between
Cbl-b and c-Cbl is that the Cbl-b UBA domain can bind Ub while
the c-Cbl UBA cannot. Ubiquitin binding mediates Cbl-b
dimerization and increases E3 ligase activity [29]. However, the
ability of Cbl-b to enable BCR endocytic trafficking to late
endosomes was not dependent on the Cbl-b ubiquitin-binding
motif. In chicken B cells, c-Cbl is recruited to the BCR and is
required for BCR surface clustering [28]. Chicken c-Cbl is also
predicted to not bind Ub, and therefore, there is likely another
unidentified functional domain, conserved between chicken c-Cbl
Figure 2. Cbl-b is recruited to the BCR and co-traffics to late endosomes. WT splenic B cells were stimulated through the BCR for the
indicated times. (A) Representative confocal images demonstrating relative locations of BCR (green), Lamp-1 (red), and Cbl-b (blue) over time. (B)
Quantitative analysis (n = 3, 30 cells/exp for each condition and time point) of co-localization over time of BCR and Cbl-b (diamond, red), BCR and
Lamp-1 (triangle, light blue), and Cbl-b and Lamp-1 (circle, dark blue).
doi:10.1371/journal.pone.0089792.g002
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Figure 3. BCR endocytic trafficking is dependent on the UBA domain of Cbl-b and independent of its ligase activity. (A) Schematic
representation of different Cbl-b mutants that were used to reconstitute Cblb2/2 splenocytes (TKB, tyrosine kinase binding domain; RF, ring finger
domain; PRO, proline rich regions; UBA, ubiquitin binding domain). Numbers above schematic refer to amino acid positions. (B) Immunoblots of
packaging cell lysates with anti-Cbl-b antibodies demonstrating the relative molecular weights of the indicated expressed Cbl-b mutants. (C)
Representative confocal images demonstrating the ability of each indicated Cbl-b mutant to reconstitute BCR endocytic trafficking in Cblb2/2
splenocytes. For these experiments, cells were stained with anti-BCR (green), anti-Lamp-1 (red), and anti-Cbl-b antibodies (blue). (D) Quantitative
analysis (n = 3, 30 cells/exp for each condition) for co-localization of BCR with Lamp-1 (* statistically similar, p,0.001 for Cbl-b WT vs. N1/2, DUBA).
doi:10.1371/journal.pone.0089792.g003
Figure 4. BCR endocytic trafficking is normal in splenocytes expressing an E3 ligase dead mutant of Cbl-b (CblbC373A). Indicated
splenocytes were stimulated through the BCR and imaged after 30 min by confocal microcopy. (A) Representative images. (B) Quantitative analysis of
three independent experiments (p,0.001 for Cblb2/2 vs CblbC373A or WT).
doi:10.1371/journal.pone.0089792.g004
Cbl-b Is Required for BCR Endocytic Trafficking
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and human and murine Cbl-b, that enables BCR endocytic
trafficking.
Previous publications have focused on Cbl-b as a negative
regulator of lymphocytes [32]. Mice deficient in Cbl-b develop an
autoimmune syndrome associated with lymphocytic infiltrates in
multiple organs [33], and they are highly susceptible to
experimental autoimmune encephalomyelitis [34] and collagen
induced arthritis [35]. Cblb2/2 T cells do not need CD28
costimulation for activation and cannot be tolerized [34]. These
phenotypic changes have been related to Cbl-b-mediated regula-
tion of PI3K [36] and PLCc1 [35], respectively. In B cells, Cbl-b
negatively regulates signaling through CD40 [37] and has been
demonstrated to bind and ubiquitinylate multiple proximal BCR
signaling components [33,38–41]. Our observation that Cbl-b is
recruited to the aggregated BCR complex provides a mechanism
by which Cbl-b could gain access to many of these signaling
substrates.
However, given the multiple negative signaling functions
ascribed to Cbl-b, the phenotype of Cblb2/2 mice is relatively
mild. Autoimmunity does not develop until after six months of age,
and potentially pathogenic immune complex deposits in glomeruli
are only observed in some aged mice (10 months old) in which
both Cbl and Cblb had been targeted in B cells [42]. By ELISA,
anti-dsDNA antibodies are detected in Cblb2/2 mice. However,
such ELISAs can be falsely positive and are not as relevant as
Crithidia luciliae immunofluorescence (IF) assays. In fact, in MRL/
Mplpr/lpr mice, TLR9 deficiency greatly diminishes anti-dsDNA
responses as measured by IF but not as measured by ELISA [43].
Thus, the available evidence indicates that the intrinsic B cell
defect in Cblb2/2 mice is not severe. We propose that this is
because Cbl-b is a complex molecule with both negative and
positive effects on peripheral B cell activation.
While the Cbl-b UBA domain is uniquely required for BCR
endocytic trafficking, it is likely that one or more additional Cbl-b
domains, conserved in c-Cbl, contribute by linking the receptor to
downstream effector mechanisms. When tyrosine phosphorylated,
Cbl proteins bind to CD2AP (CD2 adaptor protein) and the
homolog CIN85 [44–46]. CIN85 has mostly been studied in the
context of epidermal growth factor receptor (EGFR) trafficking,
while CD2AP appears to play a prominent role in TCR function
[47]. CIN85 can localize to late endosomes [48], and has been
implicated in the endocytic degradation of the EGFR [46]. T cells
from CD2AP2/2 mice have a defect in ligand-induced TCR
degradation that appears to be due to a block in trafficking to
lysosomes [47]. The exact function of CD2AP and CIN85 is not
known, although the latter has been demonstrated to function as a
scaffold for multiple molecules implicated in endocytic trafficking
[49].
Cbl-b and c-Cbl likely share another function important for
BCR endocytic trafficking. The region immediately carboxyterm-
inal to the RF domain (the RF tail) mediates phosphorylation and
degradation of Hrs [50]. Mutation of this domain both abrogates
Hrs phosphorylation and prevents fusion of EGFR-containing
early endosomes with acidic late endosomes. This phenotype is
similar to that observed for BCR trafficking in Cblb2/2
splenocytes.
Surprisingly, Cbl-b was also required for entry of TLR9 into
late endosomes. It is possible that Cbl-b regulates one or more
signaling pathways mediating TLR9 transit into late endosomes.
This possibility is consistent with our findings in anergic B cells
that defective JNK activation prevents the transit of both the BCR
and TLR9 into late endosomes [10]. It is also consistent with the
apparent dependency of MIIC maturation on Cbl-b and with the
general known interplay between BCR endocytic trafficking and
intracellular signaling [9]. Alternatively, Cbl-b could provide a
necessary linker or scaffolding function for TLR9. As Cbl-b is
recruited to the BCR, such a model would require that the BCR
and TLR9 come into close proximity before entry into late
endosomes. The strong co-localization observed between the BCR
and TLR9 in BCR-stimulated Cblb2/2 splenocytes indicates that
this is the case.
By demonstrating a unique, non-E3 dependent function for
Cbl-b, our data provide insights into how the family of Cbl ligases
may mediate different cellular functions. Deletion of Cbl-b results
Figure 5. The UBA domain of Cbl-b, in the context of c-Cbl, is sufficient for BCR endocytic trafficking. (A) Schematic representation of
Cbl-b and c-Cbl encoding constructs used to reconstitute Cblb2/2 splenocytes. Percentages represent homology between c-Cbl and Cbl-b in
indicated domains. (B) Immunoblot of PlatE cell lysates expressing indicated constructs with anti-c-Cbl antibodies. (C) Representative confocal images
of Cblb2/2 splenocytes reconstituted with virus encoding c-Cbl or c-CblDUBA-Cbl-b after stimulation through BCR for 30 minutes (n = 3). (D)
Quantitation of experiments provided in (C, BCR co-localization with Lamp-1) across three independent experiments (30 cells/exp) (p,0.001).
doi:10.1371/journal.pone.0089792.g005
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in immune hyperactivity and some features of autoimmunity. In
this regard, Cbl-b is broadly similar to c-Cbl. However, specific
mechanistic dissection indicates that the Cblb2/2 phenotype
reflects the net effect of deleting a molecule that can both enable
and suppress specific immune mechanisms. Our data also
demonstrate that Cbl-b is more than a biochemical component
Figure 6. Cbl-b is required for the endocytic transit of TLR9. (A) Representative confocal microscopic images of splenocytes from mice with
indicated genotypes. For experiments, cells were stimulated through the BCR (green) for 30 minutes then fixed and stained for TLR9 (blue) and Lamp-
1 (red)(n = 3). (B) Quantitation of experiments shown in (A) for fraction of cells demonstrating significant co-localization of TLR9 with Lamp-1 (n = 3, 30
cells/exp) (Cbl-b2/2 vs. CblbC373A or WT, p,0.001). (C) Quantitation of fractions of cells in (A) demonstrating significant co-localization between BCR
and TLR9 (n = 3, 30 cells/exp). (D) In vitro assay of T-bet induction in response to ODN 1826 or control ODN targeted through the BCR (n = 3, p,0.01).
doi:10.1371/journal.pone.0089792.g006
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of several signaling pathways. Rather, it performs an important
cell biological function by coordinating the intracellular movement
of immune recognition receptors. Therefore, Cbl-b functions in
two or more fundamental cellular processes that determine
immune responses to both self and non-self antigens.
Supporting Information
Figure S1 Normal trafficking of the ligated BCR to early
endosomes in Cblb2/2 splenocytes. (A) Cblb2/2 or WT
splenocytes were stimulated as in Figure 1 for 15 or 45 minutes
and then fixed and stained with antibodies to the early endosomal
marker EEA1 (C45B10, Cell Signaling). Shown are representative
images of results obtained from three independent experiments. In
(B) is a quantitation of the co-localization between the BCR and
EEA1 in Cblb2/2 (light grey) and WT (dark grey) (n = 3
experiments, *p = 0.002).
(TIF)
Figure S2 C-Cbl is not recruited to the aggregated BCR
complex. Cells were stimulated for 0 to 20 minutes through the
BCR, fixed, stained with either anti-Cbl-b or anti-c-Cbl antibodies
and analyzed as in Figure 2. In (A) is provided representative
images obtained two minutes after stimulation (n= 3). In (B) is a
quantitation of the co-localization between the BCR and either c-
Cbl (red, squares) or Cbl-b (blue, diamonds)(n = 3).
(TIF)
Figure S3 Both the BCR and TLR9 target the same
Lamp-12Cathepsin L+ compartment. (A) Representative
four color confocal micrographs of WT and Cblb2/2 splenocytes
stimulated with TexasRed-conjugated anti-BCR antibodies for
30 minutes. Cells were then fixed, stained with antibodies specific
for TLR9, Cathepsin L and Lamp-1 and visualized by confocal
microscopy. (B) Quantification of co-localization between different
markers in WT (dark grey) and Cblb2/2 (light grey) splenocytes.
(n = 3, *p = 8.6561026, **p= 0.0015 and ***p= 0.0005).
(TIF)
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